Abstract

For epilepsy therapy, one-third of the patients worldwide are resistant to antiepileptic drugs mainly due to the existence of the blood-brain barrier (BBB) that prevents the drugs from reaching the epileptic lesions. Here, we design a double targeting nanoparticle carrying lamotrigine (LTG) to cross the BBB and further concentrate at the neurons. We prepare the nanoparticles on a microfluidic chip by encapsulating LTG in poly(lactic-co-glycolic acid) (PLGA) to form a core (PL) and capping the core with a shell of lipids conjugated with the D-T7 peptide (targeting the BBB) and Tet1 peptide (targeting the neuron) to form D-T7/Tet1-lipids@PL nanoparticles (NPs). In vitro and in vivo experiments show that D-T7/Tet1-lipids@PL NPs have excellent neuron targeting, antiepileptic, and protecting effects. Our approach provides a new strategy for improving the therapeutic efficacy of existing antiepileptic drugs.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.